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Introduction
The bone is a dynamic tissue that is continually remodeling 
itself which is directly related to osteoclasts which erode cavities 
in bone, and osteoblasts which synthesize a new bone matrix. 
Most metabolic disorders such as osteoporosis are a result of 
the imbalance between these two types of cells (Weinstein 
and Manolagas, 2000). Glucocorticoids (GC) have potent anti-
inflammatory effects and their current oral use is strongly 
associated with serious side effects, including osteoporosis and an 
increase in fractures as a consequence (Lane and Yao, 2011). One 
of GC principal actions is to reduce osteoblast function and their 
number by apoptosis; (Chang et al., 2009). Apoptosis is regulated by 
an intrinsic process involving the activation of genes such as the 
Bcl-2, an anti-apoptotic protein member of the bcl-2 gene family 
that participates in programmed cell death (Verborgt et al., 2002).
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A B S T R A C T
Evaluate the effect of the extract of Ginkgo biloba L., Ginkgoaceae (EGb) in the Bcl-2 expression 
by osteoblasts in the femoral trabecular bone of Wistar rats with glucocorticoid-induced 
osteoporosis. Rats were divided into five groups: osteoporosis; EGb1 (28 mg/kg); EGb2 (56 mg/
kg); alendronate (0.2 mg/animal) and control. The treatments were conducted for 20 or 30 
days. The Bcl-2 expression by osteoblasts cells was evaluated in the femoral trabecular bone. 
The control group was compared with the osteoporosis-induced group (Student’s t-test). The 
other groups were analyzed by ANOVA test followed by Tukey’s test (p < 0.05). The percentage 
of Bcl-2 expression was reduced, when the control group (17.95 ± 3.45 20 days; 21.11 ± 3.43 30 
days) was compared with the osteoporosis group (10.64 ± 3.30 20 days; 9.72 ± 2.84 30 days). 
Nevertheless, this percentage increased in the EGb2 group (18.58 ± 3.41 20 days; 16.51 ± 1.80 
30 days) when compared to the osteoporosis group. The EGb increased the expression of the 
anti-apoptotic protein, suggesting a decrease in osteoblast apoptosis. 
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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The extract of Ginkgo biloba (EGb) contains 24% of flavonoids 
(kaempferol, quercetin, rutin, myricetin, among others). 
Studies have reported that in vitro quercetin and kaempferol 
stimulate the osteoprogenitor cell in the bone marrow, the 
osteoblastic differentiation and mineralization, as well as 
the inhibition of the osteoclast function (Smith and Luo, 
2004). In previous studies, we showed that GC reduced the 
percentage of the femoral trabecular bone, and the EGb was 
effective in increasing the bone mineral content of rats with 
glucocorticoid-induced osteoporosis (GIO) (Lucinda et al., 2010). 
Recently, we also demonstrated that in the alveolar mandibular 
bone, EGb reduced the Bax expression and increased the 
Bcl-2 expression by osteoblasts in rats with GIO suggesting 
a decrease of apoptosis of these cells (Lucinda et al., 2013). 
Therefore, not only did our study related the anti-apoptotic 
properties of  EGb, but also Qiao et al., 2014 demonstrated that 
EGb exhibits a significant protective effect anti-apoptotic in 
rat myocardium cells, related to the down-regulation of Bax, 
cyt-c and caspase-3. 
These studies are important to support the anti-apoptotic 
properties of this extract that could be responsible for the 
improvement in bone mineral density shown in pre-clinical 
studies (Lucinda et al., 2010; 2013). Based on these reports, we 
hypothesized that EGb could improve the expression of anti-
apoptotic proteins such as Bcl-2 not only locally in the alveolar 
bone of the mandible but also in the trabecular femoral bone. 
The present study was designed to evaluate the effect of 
EGb in the Bcl-2 expression by osteoblast cells in the femoral 
trabecular bone of Wistar rats with GIO.
Materials and methods
The methodology of the present work was approved by the 
Ethical Committee on Animal Experimentation (protocol 
number 026/2009- CEEA, Federal University of Juiz de Fora, MG, 
Brazil), which follows the international principles in ethics for 
animal experimentation.
The dry extract of Ginkgo biloba L., Ginkgoaceae (Lot no. 
20091112) was kindly supplied by JR Pharma (EPR-Farmácia 
de Manipulação e Drogaria, Co. Ltd., Juiz de Fora, Brazil), 
which was obtained from the Galena Pharmaceutical, Co. 
Ltd. (Campinas, São Paulo, Brazil) responsible for the quality 
test using the HPLC analytical methods. The test showed 
that the Ginkgo biloba extract we used was composed of 
28.2% ginkgoflavonglicosides: 8.3% of terpenolactones; 15% 
of quercetin glycosides; 10.9% of kaempferol glycosides; 2.3% 
of ishorhamnetin glycosides and less than 5 ppm of ginkgolic 
acids.
The Ginkgo biloba dry extract was coarsely crushed and 
immediately suspended in distilled water at an appropriate 
concentration for the experiment. Afterwards, the rats of the 
EGb treatment group received a daily dosage of 1 ml of the 
suspension by oral gavage at a dose level of 28 mg/kg and 56 
mg/kg of body weight.
Female Wistar rats (50 days old, weighing approximately 
100-150 g) were obtained from the vivarium of the Federal 
University of Juiz de Fora, where they were born and bred. 
Groups of three animals were housed in clear plastic cages 
with stainless steel wire lids and pinewood shavings as 
bedding, and kept in an animal room under controlled 
environmental conditions (12:12 light/dark cycle, temperature 
22oC) on closed ventilated shelves. Animals were fed rat 
chow pellets (an average of 25 g daily) and received water ad 
libitum. Osteoporosis was induced through the intramuscular 
administration of dexamethasone disodium phosphate 
(Decadron® 4 mg/ml) at the dose level of 7 mg/kg of body 
weight, once a week, for five weeks in all groups, except in 
the control group (Lucinda et al., 2010; 2013).
After the end of the osteoporosis induction, sixty animals 
were selected at random and divided evenly into five groups 
(n = 6): Osteoporosis group (dexamethasone only); EGb1 group 
(Ginkgo biloba extract 28 mg/kg); EGb2 group (Ginkgo biloba 
extract 56 mg/kg); Alendronate group (sodium alendronate 
0.2 mg/animal/day) and Control group. The Control group 
was submitted to neither osteoporosis induction nor any 
treatment. The Alendronate, EGb1 and EGb2 groups were 
treated intragastrically, once a day, for 20 days (n = 30) or 30 
days (n = 30), after osteoporosis induction. The choice of EGb 
doses was based on previous studies (Lucinda et al., 2010; 
2013). The animals were euthanized on the 21st (n = 30) and 31st 
(n = 30) days. First they were anaesthetized intraperitoneally 
with Xylazine (180 mg/kg) and Ketamine (10 mg/kg), and then 
euthanized by total exsanguination via cardiac puncture.
The right femurs were removed and fixed in 4% phosphate-
buffered formaldehyde for 24 h; decalcified in an aqueous 
solution of 5% nitric acid for two days, and then processed 
for paraffin embedding. The immunohistochemical staining 
was performed using mouse monoclonal Bcl-2 (C-2) antibody 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) against 
amino acids 1-205 of Bcl-2 of human origin. Longitudinal 
5-μm-thick sections of the femur were obtained. The 
paraffin embedded tissues were briefly deparaffinized, put 
in a solution of 0.05M citrate buffer (pH 6) to amplify the 
signal, placed in a water bath (96°C for 40 min), and then 
cooled for 20 min at room temperature. The samples were 
washed thrice in PBS (phosphate buffered saline) solution, 
5 min each time. The endogenous peroxidase activity was 
blocked using a 3% hydrogen peroxidase solution for 10 min 
and washed in three changes of PBS for 5 min each. The 
samples were then incubated individually with monoclonal 
antibody Bax overnight at 4°C at 1:500 dilutions in 1.5% 
blocking serum in PBS and washed three times with PBS 
for 5 min each.
The ABC Staining System (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA), an avidin-biotinylated horseradish 
peroxidase complex was used as a detection reagent. The 
slides were incubated for 30 min with a biotin-conjugated 
secondary antibody, approximately 1 μg/ml and washed 
in three changes of PBS for 5 min each. Subsequently they 
were incubated for 30 min with an avidin-biotin enzyme, and 
washed in three changes of PBS for 5 min each. Afterwards, 
they were incubated in peroxidase substrate for 5 min and 
washed in deionized water for 5 min. The specificity of the 
immunoreactions was checked on hematopoietic bone marrow 
cells (internal cells). Sections were counterstained with Mayer’s 
hematoxylin for 2 min. The negative controls were obtained 
by replacing the primary antibody with serum.
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The femur samples were analyzed using an optical 
microscope system Zeiss (Hallbergmoos, Germany) for digitally 
captured microphotographs. All slides were analyzed at 250× 
and 400× magnifications by a pathologist. The quantitative 
analysis was conducted by a blind evaluator, of the 
experimental groups. The Bcl-2 expression was evaluated in the 
osteoblastic cells present in the central region of the trabecular 
bone tissue of the proximal epiphysis of the femur (Fig. 1). 
The osteoblasts were counted using the imaging software Axio 
vision® (version 4.5 for Windows semi-automatic), at 250× 
magnified images; the positive osteoblasts present a variation 
of brown color (Fig. 1). For the evaluation of the percentage of 
Bcl-2 positive cells the following formula was used: % of Bcl-2 
positive osteoblasts = Bcl-2 positive osteoblast/total number of 
osteoblasts (where the total numbers of osteoblasts include the 
positive and negative cells for the Bcl-2 protein).
The data were expressed as mean ± standard deviation, 
and were analyzed for statistical significance using one-way 
analysis of variance (ANOVA), followed by Tukey’s post-hoc 
test, except for the control group. The control group was 
compared with the osteoporosis group using the Student’s 
t-test. A probability of p < 0.05 was considered statistically 
significant.
Groups (n = 6) Bcl-2 20 days (%) Bcl-2 30 days (%) % relative
Control 17.95 ± 3.45 21.11 ± 3.43 4.5
Osteoporosis 10.64 ± 3.30a 9.72 ± 2.84a 4.7
Alendronate 16.11 ± 4.70 12.06 ± 3.78 1.9
EGb1 15.17 ± 3.11 11.69 ± 1.08b 0.3
EGb2 18.58 ± 3.41c 16.51 ± 1.80c 55.8
The data are expressed by mean± standard deviation 
ap < 0.05 when comparing the control group with the osteoporosis 
one (Student`s t-test). 
bp < 0.05  when comparing all groups, except control, with EGb2 
(Tukey’s test). 
cp < 0.05 when comparing all groups, except control, with 
osteoporosis (Tukey’s test).
Table 1
Percentage of Bcl-2 expression in osteoblasts in the femoral 
trabecular bone.
In the present study, we observed that GC reduced the 
expression of Bcl-2, responsible of cell protection by binding 
to pro-apoptotic proteins, such as Bax, Bcl-xs and Bad (Gohel et 
al., 2009). It is known that the bone fragility from GC treatment 
is multi-factorial, that include the alteration of calcium and 
phosphorus metabolism, resulting in the elevation of secretion 
of  parathyroid hormone and stimulation of osteoclast activity, 
followed by a reduction in osteogenesis and osteoblast activity 
(Lane and Yao, 2011). 
The anti-apoptotic properties of EGb reported in this and 
other studies (Smith and Luo, 2004; Lucinda et al., 2013) could 
result from the antioxidant action of the flavonoids present 
in the extract, which attenuate the reactive oxygen species 
by chelating pro-oxidant transitional metal ions. Likewise, 
Brayboy et al (2001) reported that EGb was effective in 
protecting MC3T3-E1, an osteoblast-like cell, from death when 
exposed to free radicals, thus increasing their proliferation in 
vitro. Apart from this antioxidant action, EGb has an estrogenic 
effect as reported by Oh and Chung (2004), which is probably 
another mechanism to explain the increase in the Bcl-2 
expression by osteoblasts. 
Previously, it was demonstrated that EGb improves 
the percentage of alveolar bone in the mandible and in the 
trabecular bone in the femur of rats with GIO (Lucinda 
et al., 2010). Nevertheless, when searching for a possible 
mechanism to explain these results we found an important 
effect of the EGb, which was related directly to the 
expression of pro-apoptotic and anti-apoptotic proteins by 
osteoblasts in the mandibular alveolar bone. Nevertheless, 
the positive effects of EGb in bone were not limited to the 
mandible, as before-mentioned. The present study showed 
that EGb was effective in improving the expression of Bcl-2 
in the femoral trabecular bone suggesting that one of the 
mechanisms involved in the bone increase (Lucinda et al., 
2010) is to reduce the osteoblast death caused by the use 
of GC.
In conclusion, as the EGb increases the expression of Bcl-2 
by osteoblasts in the femoral trabecular bone, this study could 
form the basis for further clinical studies of the potential effect 
of EGb in the GIO.
Results and discussion
Table 1 shows that the percentage of Bcl-2 expression of 
osteoblasts in the femoral trabecular bone was significantly 
lower in the osteoporosis group when compared with the 
control group (20 and 30 days). During the 20 and 30 days of 
treatment, the expression of Bcl-2 increased significantly in 
the EGb2 group, however the alendronate group didn’t show a 
significant increase when compared with the osteoporosis one.
Pre-clinical studies showed that EGb has a potential role 
in the treatment of GIO (Lucinda et al., 2010; 2013), however, 
to this day, the extract is not used in the clinical treatment of 
osteoporosis. Nevertheless, pre-clinical studies are important 
to clear the mechanisms that could explain the effect of EGb 
in osteoporosis.
Figure 1 – Bcl-2 expression by osteoblasts in the trabecular 
bone tissue of the proximal epiphysis of the femur. The 
red arrows show the negative osteoblasts and the black 
arrows show the positive osteoblasts. A: Control group; B: 
Osteoporosis group; C: alendronate group; D: EGb1 group; E: 
EGb2 group. Original magnification 400×.
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